Shaperon (XKRX:378800) Common Stock : ₩15,071.52 Mil (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Shaperon Common Stock?

Shaperon's quarterly common stock increased from Mar. 2024 (₩11,535.52 Mil) to Jun. 2024 (₩15,071.52 Mil) but then stayed the same from Jun. 2024 (₩15,071.52 Mil) to Sep. 2024 (₩15,071.52 Mil).

Shaperon's annual common stock increased from Dec. 2021 (₩9,701.19 Mil) to Dec. 2022 (₩11,238.39 Mil) and increased from Dec. 2022 (₩11,238.39 Mil) to Dec. 2023 (₩11,535.52 Mil).

Shaperon Common Stock Historical Data

The historical data trend for Shaperon's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shaperon Common Stock Chart

Shaperon Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

297.00

1,485.00

9,701.19

11,238.39

11,535.52

Shaperon Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Common Stock	Get a 7-Day Free Trial							11,535.52	11,535.52	11,535.52	15,071.52	15,071.52

Shaperon Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Shaperon Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shaperon Inc (XKRX:378800) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

Gangnam Ace Tower G9, Suie 218 & 606, 174-10 Jagok-ro, Gangnam-gu, Seoul, KOR, 06373

Website

http://www.shaperon.com

Shaperon Inc is a developer of innovative inflammasome inhibitors and nanobody therapeutics intended to develop novel treatments for various chronic inflammatory diseases, including atopic dermatitis, systemic inflammatory response syndrome, neuroinflammatory diseases, and chronic inflammation. It offers a range of drug candidates, including a gel-type atopic dermatitis drug for use in the treatment of systemic inflammatory response syndrome, neuroinflammatory diseases and for treating chronic inflammation. The company also provides immunotherapeutic products and a single-domain neutralizing antibody, enabling clients to improve patient's quality of life by developing safe and efficacious drugs and immunotherapies.

Shaperon Headlines

No Headlines